Theravance Biopharma, Inc.TBPHNASDAQ
LOADING
|||
Switch Symbol:
EPS Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
-93.58%
↓ 133% below average
Average (39q)
286.33%
Historical baseline
Range
High:11136.36%
Low:-101.73%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -93.58% |
| Q2 2025 | 503.70% |
| Q1 2025 | 12.90% |
| Q4 2024 | -19.23% |
| Q3 2024 | 23.53% |
| Q2 2024 | -41.67% |
| Q1 2024 | -41.18% |
| Q4 2023 | 0.00% |
| Q3 2023 | 39.29% |
| Q2 2023 | 20.00% |
| Q1 2023 | -66.67% |
| Q4 2022 | -101.73% |
| Q3 2022 | 11136.36% |
| Q2 2022 | 67.65% |
| Q1 2022 | 22.73% |
| Q4 2021 | 8.33% |
| Q3 2021 | 40.00% |
| Q2 2021 | 35.48% |
| Q1 2021 | -34.78% |
| Q4 2020 | 20.69% |
| Q3 2020 | -16.00% |
| Q2 2020 | 28.57% |
| Q1 2020 | -19.66% |
| Q4 2019 | -11.43% |
| Q3 2019 | -45.83% |
| Q2 2019 | 45.45% |
| Q1 2019 | -43.48% |
| Q4 2018 | 16.36% |
| Q3 2018 | -44.74% |
| Q2 2018 | 37.70% |
| Q1 2018 | 25.61% |
| Q4 2017 | -29.13% |
| Q3 2017 | 0.00% |
| Q2 2017 | 0.00% |
| Q1 2017 | 6.62% |
| Q4 2016 | -86.30% |
| Q3 2016 | 31.13% |
| Q2 2016 | 3.64% |
| Q1 2016 | 10.57% |
| Q4 2015 | 12.14% |